Sorry Gary, can’t agree there. First of all a contract manufacturer is not going to partner with a drug company. That ruins their business, and they have no true advantages to offer. Secondly, NWBO has technology to manufacture its drug, and CRL does not have that technology. They don’t need clean rooms. That would be a more expensive and less scalable way to make their product.
CRL has no credibility in the medical space. They neither sell drugs nor develop them. They have no experience in those areas. And as I said, they are a contract manufacturer, not a pharma or biotech company. There is nothing they can offer. The also do not have anywhere near the capital to give up their own business and move into a completely new business. Not to run both businesses even if the could do that and start competing with their clients.
That kind of partnership or merger simply does not happen. They want to be paid by NWBO, not pay for and distribute DCVax-L.
Market Data 
Markets 
